Adrian Adams is the Chairman and CEO at Impel Pharmaceuticals.. Adrian Adams was appointed POZEN’s Chief Executive Offer and elected to its Board of Directors on June 1, 2015. Prior to joining POZEN, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo. International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix,
